Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2015; 5(10):1154-1165. doi:10.7150/thno.12398 This issue Cite

Research Paper

Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors

Lingling Geng, Zihua Wang, Xiaoliang Yang, Dan Li, Wenxi Lian, Zhichu Xiang, Weizhi Wang, Xiangli Bu, Wenjia Lai, Zhiyuan Hu✉, Qiaojun Fang✉

CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, China

✉ Corresponding authors: Qiaojun Fang, National Center for Nanoscience and Technology, Beijing 100190, China. Phone: +86-10-82545562; Fax: +86-10-82545643; E-mail: fangqjcn. Zhiyuan Hu, National Center for Nanoscience and Technology, Beijing More

Citation:
Geng L, Wang Z, Yang X, Li D, Lian W, Xiang Z, Wang W, Bu X, Lai W, Hu Z, Fang Q. Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. Theranostics 2015; 5(10):1154-1165. doi:10.7150/thno.12398. https://www.thno.org/v05p1154.htm
Other styles

File import instruction

Abstract

Graphic abstract

To identify peptides with high affinity and specificity against human epidermal growth factor receptor 2 (HER2), a series of peptides were designed based on the structure of HER2 and its Z(HER2:342) affibody. By using a combination protocol of molecular dynamics modeling, MM/GBSA binding free energy calculations, and binding free energy decomposition analysis, two novel peptides with 27 residues, pep27 and pep27-24M, were successfully obtained. Immunocytochemistry and flow cytometry analysis verified that both peptides can specifically bind to the extracellular domain of HER2 protein at cellular level. The Surface Plasmon Resonance imaging (SPRi) analysis showed that dissociation constants (KD) of these two peptides were around 300 nmol/L. Furthermore, fluorescence imaging of peptides against nude mice xenografted with SKBR3 cells indicated that both peptides have strong affinity and high specificity to HER2 positive tumors.

Keywords: structure-based design, HER2 targeted peptide, breast cancer, MD simulation

Citation styles

APA
Geng, L., Wang, Z., Yang, X., Li, D., Lian, W., Xiang, Z., Wang, W., Bu, X., Lai, W., Hu, Z., Fang, Q. (2015). Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. Theranostics, 5(10), 1154-1165. https://doi.org/10.7150/thno.12398.

ACS
Geng, L.; Wang, Z.; Yang, X.; Li, D.; Lian, W.; Xiang, Z.; Wang, W.; Bu, X.; Lai, W.; Hu, Z.; Fang, Q. Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. Theranostics 2015, 5 (10), 1154-1165. DOI: 10.7150/thno.12398.

NLM
Geng L, Wang Z, Yang X, Li D, Lian W, Xiang Z, Wang W, Bu X, Lai W, Hu Z, Fang Q. Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. Theranostics 2015; 5(10):1154-1165. doi:10.7150/thno.12398. https://www.thno.org/v05p1154.htm

CSE
Geng L, Wang Z, Yang X, Li D, Lian W, Xiang Z, Wang W, Bu X, Lai W, Hu Z, Fang Q. 2015. Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. Theranostics. 5(10):1154-1165.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use